An observational study in Dengue Fever, sponsored by National Center for Gastroentestinal and Liver Disease. Completed at 1 site in Sudan. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by National Center for Gastroentestinal and Liver Disease · Observational
Dengue fever is a common mosquito-borne viral infection in many tropical regions, including Sudan. Some patients develop severe forms of the disease, such as dengue hemorrhagic fever, which can lead to plasma leakage, bleeding, organ involvement, and life-threatening complications. Early identification of patients at risk of severe disease is essential for timely management and improved outcomes.
This study aims to describe the abdominal ultrasound findings in patients diagnosed with dengue fever and to examine how these findings relate to clinical features and blood test results, particularly low platelet counts (thrombocytopenia). Ultrasound is a non-invasive and widely available imaging method that may help detect complications early and guide clinical decision-making.
In this retrospective cross-sectional study, medical records and archived abdominal ultrasound images of 150 patients with laboratory-confirmed dengue infection were reviewed. The study evaluated the frequency of findings such as gallbladder wall thickening, fluid accumulation in the abdomen and chest, liver and spleen enlargement, and rare complications like internal bleeding. These imaging findings were then compared with patient demographics and laboratory results to determine their clinical significance.
By identifying the most common ultrasound features and their association with disease severity, this study seeks to support the use of abdominal ultrasound as a practical tool for risk assessment and monitoring in dengue-endemic settings. The results may help clinicians recognize severe dengue earlier and improve patient management in resource-limited environments.
Dengue fever is a major public health concern in endemic regions, with a wide clinical spectrum ranging from mild illness to severe dengue hemorrhagic fever characterized by plasma leakage, bleeding, and organ involvement. Early identification of patients at risk of progression to severe disease remains a clinical challenge, particularly in resource-limited settings where advanced diagnostic tools may not be readily available.
Abdominal ultrasonography has emerged as a useful, non-invasive imaging modality for detecting early signs of plasma leakage and organ involvement in dengue infection. Findings such as gallbladder wall thickening, ascites, pleural effusion, hepatomegaly, and splenomegaly have been reported to correlate with disease severity. However, data on the utility of these sonographic features in Sudanese populations remain limited.
This study was designed as a retrospective cross-sectional analysis conducted in Kassala, Sudan, covering the period from July 2024 to February 2025. It utilized archived abdominal ultrasound images and corresponding clinical and laboratory data of patients with NS1-confirmed dengue infection. The study focused on systematically evaluating predefined sonographic parameters and examining their relationship with hematological indicators, particularly platelet count as a marker of disease severity.
Statistical analysis was performed to determine the strength of associations between imaging findings and clinical severity indicators. Special attention was given to identifying imaging patterns that may serve as early predictors of severe disease, as well as documenting less common but clinically significant complications.
The findings of this study are intended to contribute to the existing body of evidence supporting the role of abdominal ultrasound in dengue management. By clarifying its prognostic value, the study aims to inform clinical practice and encourage the incorporation of ultrasound into routine assessment and risk stratification protocols in dengue-endemic and resource-constrained settings.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
This study's enrollment of 150 is below the median of 595 across 80 observational studies indexed under Dengue.
Browse Dengue studies →National Center for Gastroentestinal and Liver Disease is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consisted of patients with confirmed dengue infection who presented to healthcare facilities in Kassala, Sudan, between July 2024 and February 2025. All included patients had undergone abdominal ultrasonography as part of their clinical evaluation. Demographic, clinical, laboratory, and imaging data were retrospectively collected and analyzed to assess the relationship between ultrasound findings and disease severity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort includes patients with laboratory-confirmed dengue infection (NS1 positive) who underwent abdominal ultrasonography during their illness. Clinical data, hematologic parameters (including platelet counts), and archived ultrasound findings were retrospectively reviewed to assess the association between sonographic features and disease severity.
Correlation Between Platelet Count and Abdominal Ultrasonographic Findings in Patients With Dengue Infection
Correlation between platelet count (cells/µL), measured by complete blood count at hospital presentation, and the presence of abdominal ultrasonographic findings including gallbladder wall thickening (mm), ascites (present/absent), and hepatomegaly (present/absent), assessed by abdominal ultrasound at hospital presentation.
Time frame: At hospital presentation/admission (retrospective data from July 2024 to February 2025).
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2024 to primary completion in Feb 2025, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Center for Gastroentestinal and Liver Disease